BrainsWay Invests $16M in Neurolief, $2.3M in Axis Mental Health Services

BrainsWay Ltd. has made strategic investments to expand its reach in mental health treatment markets, focusing on noninvasive neurostimulation technologies. The company closed a $5 million convertible note loan investment in Neurolief Ltd., a developer of the Proliv™Rx device, which, pending FDA approval, would become the first wearable, non-invasive brain neuromodulation device for major depressive disorder (MDD) treatment available outside clinical settings. This move aligns with BrainsWay’s goal to increase access to mental health therapies beyond traditional clinics. Additionally, BrainsWay invested $2.3 million, with potential for $1 million more, to acquire a minority stake in Axis Integrated Mental Health, a Colorado-based management services organization for mental health clinics, supporting the expansion of innovative treatments including BrainsWay's Deep TMS therapy. These investments are part of BrainsWay's broader strategy to accelerate awareness, enhance treatment accessibility, and boost growth among leading mental health providers. CEO Hadar Levy emphasized that these partnerships allow healthcare providers to expand services and support patients more effectively through cutting-edge neurostimulation therapies.